Skip to content

Bausch Health

US · BHC #2722 by market cap Listed 1970
8.22 -0.34 -3.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:46

About Bausch Health

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Founded
2002
CEO
Mr. Thomas J. Appio
Employees
20,300
Headquarters
Laval, Québec, Canada
Fiscal year end
12-31
Website
bauschhealth.com

Company profile

Exchange
US
Symbol
BHC
Market-cap rank
#2722
Listing date
1970-01-01
Market cap
3.08B
Float cap
2.14B
Shares out
374.27M
Float shares
260.85M

Sectors & themes

Drug Manufacturers - Specialty & Generic

Browse all sectors & themes

Quote time 2026-11-20 19:46:13 · For reference only, not investment advice and not tailored to your situation.

Bausch Health discussion 0 comments

Add a comment